Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause; Draft Guidance for Industry

The N=1 Collaborative (N1C), a nonprofit consortium of clinicians, researchers, and patient advocates, supports the draft guidance as a necessary step for developing individualized therapies for rare genetic diseases. They recommend specific improvements, including making data sharing a requirement, calibrating CMC standards for small-batch manufacturing, expanding the platform concept to multiple genes, and establishing a formal process for developing clinical effectiveness standards.

The Critical Path Institute (C-Path), a nonprofit organization, supports the FDA's draft guidance on the Plausible Mechanism Framework for developing individualized therapies. They recommend providing greater clarity on statutory alignment, evidentiary expectations for mechanistic data, the role of biomarkers, and the integration of natural history data and quantitative modeling to ensure consistent regulatory decision-making.

The Academy of Managed Care Pharmacy (AMCP) supports the FDA's use of the Plausible Mechanism Framework to develop individualized therapies for ultra-rare genetic conditions. They advocate for clearer definitions of the framework's scope, standardized protocols for real-world evidence (RWE) collection, and increased transparency regarding post-marketing evidence to support coverage and reimbursement decisions.

The commenters, representing academic and medical institutions (Arizona State University, Toulouse School of Economics, and Harvard Medical School), support the FDA's move toward a "plausible mechanism" framework for N-of-1 therapies but argue it should move further toward a service-based model. They advocate for replacing one-time premarket approval with continuous oversight and mandatory data sharing to address the unique challenges of individualized genetic treatments.

The commenter, who appears to be a clinician or researcher working with rare diseases, supports the draft guidance but suggests specific improvements. They advocate for allowing multiple outcome measures in clinical trials for small populations, making autopsies the default option in consent forms, and strengthening data-sharing requirements into mandatory standards.

Cureledger, Inc., a life data trust for rare diseases, supports the draft guidance and the Plausible Mechanism Framework for accelerating drug development. They recommend that the final guidance include consolidated data standards for natural history studies, enhanced privacy protections for small populations, and clear protocols for data lifecycle and custody to ensure data persistence.

Vyona Health, a health technology company, supports the proposed guidance but recommends adding specific methodological standards for causal inference, multi-omic causal modeling for biomarkers, and federated evidence generation. They argue these additions will improve the scientific rigor and practical feasibility of using the Plausible Mechanism Framework for rare diseases.